(P117) Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1 RAs) on Glycemic Control and Weight Outcomes in Type 2 Diabetes

This observational cohort study evaluated HbA1c and weight changes in T2D and their association with OW GLP-1 RA and how they are affected by OW GLP-1 RA vs DPP-4i. Using an index date of the first OW GLP-1 RA prescription claim, pre- /post-index analyses showed 41.4% of patients achieved a post-index HbA1c <7%; 27.7% had weight loss ≥5%. After adjustment for imbalanced covariates, regression modeling showed that the odds of achieving HbA1c and weight-loss goals were more than twice as great with once-weekly GLP-1 RA than with DPP-4 inhibitors.